Comparative Stroke, Bleeding, and Mortality

ARTICLE IN PRESS References 1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus war- farin in patients with atrial fibrillation. N Engl J Med . 2009;161: 1139–1151. 2. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med . 2011;365:883–891. 3. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med . 2011;365:981–992. 4. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med . 2013;369:2093–2104. 5. Lip GY, Pan X, Kamble S, et al. Major bleeding risk among non-val- vular atrial fibrillation patients initiated on apixaban, dabigatran, rivar- oxaban or warfarin: a "real-world" observational study in the United States. Int J Clin Pract . 2016;70(9):752–763. 6. Lip GYH, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients ini- tiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost . 2016;116(5):975–986. 7. Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest . 2016;150(6):1302–1310. 8. Deitelzweig S, Luo X, Gupta K, et al. Comparison of effectiveness and safety of treatment with apixaban vs other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Curr Med Res Opin . 2017;33:1745–1754. 9. Adeboyeje G, Sylwestrzak G, Barron JJ, et al. Major bleeding risk dur- ing anticoagulation with warfarin, dabigatran, apixaban, or rivaroxa- ban in patient s with nonvalvular atrial fibrillation. J Manag Care Spec Pharm . 2017;23:968–978. 10. Hernandez I, Zhang Y, Saba S. Comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in newly diagnosed atrial fibrillation. Am J Cardiol . 2017;120:1813–1819. 11. Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND. Gastrointestinal safety of direct oral anticoagulants: a large popula- tion-based study. Gastroenterology . 2017;152:1014–1022. 12. Ray WA. Evaluating medication effects outside of clinical trials: new- user designs. Am J Epidemiol . 2003;158:915–920. 13. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijins JGM. Refin- ing clinical risk stratification for predicting stroke and thrombo- embolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest . 2010;137:263–272. 14. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest . 2010;138(5):1093–1100. 15. Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci . 2010;25:1–21. 16. Imbens GW. The role of the propensity score in estimating dose- response functions. Biometrika . 2000;87(3):706–710. 17. Austin PC. Balance diagnostics for comparing the distribution of base- line covariates between treatment groups in propensity-score matched samples. Stat Med . 2009;28:3083–3107. 18. Tirschwell DL, Longstreth WT. Validating administrative data in stroke research. Stroke . 2002;33(10):2465–2470. 19. Roumie CL, Mitchel E, Gideon PS, Varas-Lorenzo C, Castellsague J, Griffin MR. Validation of ICD-9 codes with a high positive predictive value for incident stroke resulting in hospitalization using Medicaid health data. Pharmacoepidemiol Drug Saf . 2008;17(1):20–26. 20. Kokotaila RA, Hill MD. Coding of stroke and stroke risk factors using International Classification of Diseases , revision 9 and 10. Stroke . 2005;36(8):1776–1781. 21. Cunningham AW, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA. An automated database definition for serious bleed- ing due to oral anticoagulant use. Pharmacoepidemiol Drug Saf . 2011;20:560–566. 22. Hill ME, Rosenwaike I. The Social Security Administration’s Death Mas- ter File: the completeness of death reporting at older ages. Soc Secur Bull . 2001-2002;64(1):45-51. Available at: http://www.socialsecurity.gov/pol- icy/docs/ssb/v64n1/v64n1p45.pdf . Accessed June 14, 2018. 23. Xie J, Liu C. Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med . 2005;24:3089–3110. 24. Dlott JS, George RA, Huang X, et al. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Cir- culation . 2014;129:1407–1414. 25. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and pre- diction of adverse events in patients with atrial fibrillation: a system- atic review. Circ Cardiovasc Qual Outcomes . 2008;1:84–91. 26. Bj € o rck F, Renlund J, Lip GYH, Wester P, Svensson PJ, Sj € a lander A. Outcomes in a warfarin-treated population with atrial fibrillation. JAMA Cardiol . 2016;1:172–180. 27. US Food and Drug Administration. 2011 Meeting materials, Cardiovas- cular and Renal Drugs Advisory Committee. Available at: https://way- back.archive-it.org/7993/20170403223812/https://www.fda.gov/Advisor- yCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRe- nalDrugsAdvisoryCommittee/ucm250287.htm . Accessed June 14, 2018. 28. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. JAMA . 2001;285:2370–2375. Funding: The US Food and Drug Administration, through an inter- agency agreement between it and the Centers for Medicare & Medicaid Services. Conflict of Interest: None of the authors have any conflicts of interest to declare. Authorship: All authors had access to the data and a role in writing the manuscript. The views expressed are the authors’ and not necessarily those of the Centers for Medicare & Medicaid Services, the Food and Drug Administration, or the Department of Health and Human Services. Graham et al Comparative Safety and Effectiveness of Anticoagulants in Atrial Fibrillation 9